Introduction:
Novo Catalent, a leading provider of advanced technology and outsourcing solutions for the global biotechnology industry, has announced a new deal that is set to disrupt the cell and gene therapy (CGT) outsourcing market. This partnership will provide customers with a comprehensive offering of cell and gene therapy development and manufacturing services, including support for viral vector manufacturing, plasmid DNA production, and cell therapy manufacturing.
- Novo Catalent has entered into a strategic partnership with Paragon Gene Therapy, a leading viral vector development and manufacturing company.
- The partnership aims to create a one-stop-shop for CGT development and manufacturing services, offering customers a seamless and integrated solution for their needs.
- This collaboration will enable Novo Catalent to expand its capabilities in the CGT space and provide customers with a broader range of services.
- The deal will also help Paragon Gene Therapy gain access to Novo Catalent’s extensive customer base and global infrastructure.
- This partnership has the potential to shake up the CGT outsourcing market and drive further innovation in the field.
Conclusion:
The strategic partnership between Novo Catalent and Paragon Gene Therapy is set to disrupt the CGT outsourcing market by offering customers a comprehensive and integrated solution for their development and manufacturing needs. This collaboration has the potential to drive further innovation in the field and provide customers with a broader range of services. With Novo Catalent’s extensive customer base and global infrastructure, this partnership is primed to shake up the CGT outsourcing space.
